Clene (NASDAQ:CLNN) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Clene (NASDAQ:CLNN) announced its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14), Zacks reports. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.03 million.

Clene Stock Down 3.4%

CLNN opened at $5.72 on Friday. Clene has a 52 week low of $2.28 and a 52 week high of $13.50. The business has a fifty day simple moving average of $4.98 and a 200-day simple moving average of $6.70. The firm has a market cap of $62.06 million, a P/E ratio of -2.20 and a beta of 0.62.

Insider Activity

In related news, major shareholder Chidozie Ugwumba sold 15,284 shares of the stock in a transaction dated Thursday, January 29th. The stock was sold at an average price of $4.32, for a total transaction of $66,026.88. Following the transaction, the insider owned 565,045 shares of the company’s stock, valued at approximately $2,440,994.40. This represents a 2.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders sold 293,754 shares of company stock valued at $1,587,329. 35.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Clene

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Clene during the second quarter worth about $47,000. State Street Corp boosted its stake in shares of Clene by 138.4% in the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the period. PEAK6 LLC acquired a new position in shares of Clene in the fourth quarter valued at approximately $294,000. Geode Capital Management LLC grew its holdings in shares of Clene by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after purchasing an additional 6,090 shares in the last quarter. Finally, Scoggin Management LP increased its stake in Clene by 42.8% during the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock worth $558,000 after buying an additional 42,750 shares during the period. 23.28% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CLNN. UBS Group reaffirmed a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a report on Friday, January 9th. Benchmark restated a “buy” rating on shares of Clene in a report on Thursday, December 4th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $48.00 price target on shares of Clene in a research report on Friday. Finally, D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Thursday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Clene has a consensus rating of “Moderate Buy” and a consensus price target of $32.60.

Trending Headlines about Clene

Here are the key news stories impacting Clene this week:

• Positive Sentiment: Company secured an oversubscribed registered direct offering of more than $28 million and has an initial financing tranche of over $6 million, which management says provides runway into Q3 and, if completed, into 2027 — a near-term cash cushion ahead of potential NDA milestones. GlobeNewswire: Full Year 2025 Results
• Positive Sentiment: Management scheduled an in-person Type C FDA meeting by end of Q1 to discuss biomarker and survival data for CNM‑Au8; positive feedback could enable an NDA filing under accelerated approval by end of Q2 — a material regulatory catalyst. GlobeNewswire: FDA meeting
• Positive Sentiment: Several brokers reiterated buy ratings with aggressive price targets (Canaccord affirmed a $48 target; D. Boral Capital reiterated buy with a $23 target), which can support speculative interest ahead of clinical/regulatory readouts. TickerReport: Canaccord note AmericanBankingNews: D. Boral
• Neutral Sentiment: Reported short-interest data is effectively zero/ambiguous (entries show 0 shares and NaN changes), so short pressure does not appear to be a material driver currently.
• Negative Sentiment: Clene reported quarterly EPS of ($0.88), missing the consensus ($0.74) by $0.14; revenue was very small ($0.08M). The EPS miss likely drove near-term selling despite the tiny revenue beat. Quarterly results (press release)
• Negative Sentiment: HC Wainwright published multi-quarter EPS estimates that show continued losses (Q1–Q4 2026 EPS forecasts around ($0.45)–($0.51); full-year consensus remains large negative), underscoring ongoing cash burn and delayed path to profitability.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).